These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 19111385)

  • 21. Prostate-specific antigen testing for the early detection of prostate cancer.
    Kirby R; Fitzpatrick J
    BJU Int; 2004 Nov; 94(7):966-7. PubMed ID: 15541108
    [No Abstract]   [Full Text] [Related]  

  • 22. Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.
    Vickers A; Vertosick EA; Sjoberg DD; Hamdy F; Neal D; Bjartell A; Hugosson J; Donovan JL; Villers A; Zappala S; Lilja H
    J Urol; 2018 Jun; 199(6):1470-1474. PubMed ID: 29366640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen and other prostate cancer markers.
    Stenman U; Finne P; Zhang W; Leinonen J
    Urology; 2000 Dec; 56(6):893-8. PubMed ID: 11113726
    [No Abstract]   [Full Text] [Related]  

  • 24. Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes.
    Flaig TW; Nordeen SK; Lucia MS; Harrison GS; Glodé LM
    J Urol; 2007 Apr; 177(4):1229-37. PubMed ID: 17382696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment: a clinical conundrum in the PSA era.
    Punnen S; Nam RK
    Surg Oncol; 2009 Sep; 18(3):192-9. PubMed ID: 19282170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p2PSA but not total and free PSA increases after myocardial infarction: results of a preliminary investigation.
    Lippi G; Aloe R; Cervellin G
    Int J Cardiol; 2011 Nov; 153(1):119. PubMed ID: 21968074
    [No Abstract]   [Full Text] [Related]  

  • 27. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate specific antigen and other markers for prostate cancer.
    Schröder FH
    J Urol; 2006 Apr; 175(4):1199-200. PubMed ID: 16515959
    [No Abstract]   [Full Text] [Related]  

  • 29. Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?
    Jackson BR
    Arch Pathol Lab Med; 2013 Mar; 137(3):308-9. PubMed ID: 22799565
    [No Abstract]   [Full Text] [Related]  

  • 30. [Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer].
    Mazzola CR; Ghoneim T; Shariat SF
    Prog Urol; 2011 Jan; 21(1):1-10. PubMed ID: 21193139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomarkers for the early detection of cancer: an inflammatory concept.
    Roy HK; Khandekar JD
    Arch Intern Med; 2007 Sep; 167(17):1822-4. PubMed ID: 17893302
    [No Abstract]   [Full Text] [Related]  

  • 32. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program.
    Barry MJ; Fleming C; Coley CM; Wasson JH; Fahs MC; Oesterling JE
    Urology; 1995 Oct; 46(4):445-61. PubMed ID: 7571211
    [No Abstract]   [Full Text] [Related]  

  • 33. Re: Clinical performance of serum isoform (-2)proPSA (p2PSA) and its derivatives, namely %p2PSA and PHI (Prostate Health Index) in men younger than 60 years of age: results from a multicentric European study.
    Taneja SS
    J Urol; 2014 Aug; 192(2):421. PubMed ID: 25034991
    [No Abstract]   [Full Text] [Related]  

  • 34. Prostate cancer screening; is this a teachable moment?
    Brawley OW
    J Natl Cancer Inst; 2009 Oct; 101(19):1295-7. PubMed ID: 19720970
    [No Abstract]   [Full Text] [Related]  

  • 35. Diagnosis, characterization and potential clinical relevance of prostate cancer detected at low PSA ranges.
    Schröder FH
    Eur Urol; 2001 Apr; 39 Suppl 4():49-53. PubMed ID: 11340292
    [No Abstract]   [Full Text] [Related]  

  • 36. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 37. In this issue: mini-theme on geriatric care and cancer screening.
    Bowman MA; Neale AV
    J Am Board Fam Med; 2009; 22(3):231-3. PubMed ID: 19429726
    [No Abstract]   [Full Text] [Related]  

  • 38. [Usefulness of PSA isoform].
    Okegawa T
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():254-8. PubMed ID: 22207981
    [No Abstract]   [Full Text] [Related]  

  • 39. Detecting and treating prostate cancer: a surgeon's perspective.
    Buchan NC
    N Z Med J; 2012 Apr; 125(1353):6-8. PubMed ID: 22522266
    [No Abstract]   [Full Text] [Related]  

  • 40. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.
    Shimbo M; Tomioka S; Sasaki M; Shima T; Suzuki N; Murakami S; Nakatsu H; Shimazaki J
    Jpn J Clin Oncol; 2009 Nov; 39(11):727-31. PubMed ID: 19674994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.